A pivotal decade for bispecific antibodies?
ABSTRACTBispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantia...
Main Authors: | Marlena Surowka, Christian Klein |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2321635 |
Similar Items
-
Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors
by: Luigi Liguori, et al.
Published: (2022-11-01) -
Bispecific Antibodies: From Research to Clinical Application
by: Jiabing Ma, et al.
Published: (2021-05-01) -
Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy
by: Carlos Carrasco-Padilla, et al.
Published: (2022-12-01) -
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review
by: Andrea Visentin, et al.
Published: (2024-03-01) -
Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China
by: Zhonghan Zhang, et al.
Published: (2021-08-01)